Navigation Links
Through 2018, Five New Drugs Will Launch for the Treatment of Myelodysplastic Syndromes
Date:2/6/2013

BURLINGTON, Mass., Feb. 6, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2018, five new drugs will launch for the treatment of myelodysplastic syndromes (MDS), three of which are expected to offer much-needed second-line therapeutic options in the hypomethylating agent (HMA)-refractory higher-risk MDS population. Currently, there is only one curative treatment for MDS -- allogeneic hematopoietic stem cell transplant (HSCT). However, old age and poor general performance status classifies approximately 75 percent of patients as ineligible for this treatment.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

Between 2004 and 2006, the U.S. MDS market expanded when the first drug therapy options were approved for the indication -- azacitidine (Celgene's Vidaza), lenalidomide (Celgene's Revlimid) and decitabine (Eisai/MGI Pharma's Dacogen). No new therapies have been approved in the United States for MDS since 2006; only azacitidine has been approved for MDS in Europe, although experts believe an EU approval for lenalidomide is imminent.

According to Niche Markets and Rare Diseases: Myelodysplastic Syndromes, azacitidine is the leading therapeutic option for the disease in both the U.S. and Europe. Decision Resources anticipates expansion of MDS therapeutic options with the approval of five drugs between 2014-2018: oral azacitidine for transfusion-dependent lower-risk MDS; Onconova/Baxter's intravenous formulation of rigosertib (Estybon) for HMA-refractory higher-risk MDS; Merck's vorinostat (Zolinza) for combination therapy with azacitidine in higher-risk MDS; Cyclacel's oral sapacitabine for HMA-refractory higher-risk MDS; and GlaxoSmithKline's eltrombopag (Revolade) for HMA-refractory higher-risk MDS, with a focal goal of reducing thrombocytopenia. Onconova also has an oral formulation of rigosertib in development for lower-risk patients.

"The near-term MDS drug market will grow modestly as lenalidomide obtains approval in Europe, but the next wave of noteworthy market growth will come between 2014 and 2018," said Decision Resources Vice President Kim Crowell . "While experts acknowledge that the approvals of azacitidine and lenalidomide were groundbreaking, they also report significant remaining unmet need in MDS. Citing the dearth of second-line options for higher-risk MDS patients, experts are hopeful that several Phase II and III drugs will provide valuable alternative therapeutic options, although they do not expect any drug during the next decade to completely shift or uproot the MDS therapeutic landscape. Improving overall survival, without sacrificing quality of life, is the key therapeutic goal in higher risk MDS patients, while functional quality of life via hematologic improvement is the primary goal in lower-risk patients."

About Myelodysplastic Syndromes

Myelodysplastic Syndromes is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Breakthrough Procedure Provides Relief for Acid Reflux
2. The Treatment Landscape for Thyroid Carcinoma Will Change Dramatically Through 2021
3. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
4. Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need
5. Executives guide entrepreneurs through science business maze
6. Seeing Life Through Many Lenses: Different Ophthalmic Lenses for Different Lifestyles
7. Brazilian, Indian and Chinese Orthopedic Markets to See Strong Growth Through 2017
8. Breakthrough Research Could Create Sea Change in Global HIV Diagnosis: New Handheld Mobile Device Performs Laboratory-Quality HIV Testing
9. Maximizing the Effectiveness of Market Research Groups through Outsourcing and Automation
10. New Breakthrough Treatment For Evaporative Dry Eye Disease Introduced By Dry Eye Specialist, Mark R. Mandel, M.D.
11. Elseviers Clinical Pharmacology Now Accessible Through Elsevier Infobutton
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
(Date:2/23/2017)... SEOUL , Südkorea, 23. Februar 2017 ... LED für Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache ... kurzwellige ultraviolette Strahlung im Bereich zwischen 200 und 280 nm ... Ausbreitung von Bakterien, indem es ihre DNA zerstört. Das ... 280 nm. ...
(Date:2/23/2017)... , 23. Februar 2017 Im Rahmen ... eine nationale Wirtschaftszone in der südwestlichen chinesischen Provinz Guizhou, 2017 ... Errichtung einer Innovationsplattform aktiv an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. ... Continue Reading ... ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 2017 , ... In the Health Care IT campaign, Robert Herjavec discusses health ... if you will be attacked, but when.” However, he and many others involved highlight ... , Improvements in auditing and monitoring have taken security in health care a very ...
(Date:2/24/2017)... ... ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” (published by ... Schanssema describes the tragedies he saw, as well as his struggles with grief and ... unsure of the career path he wanted to take, found fulfillment in a career ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... Prophecy concerning this present generation. Yisrayl makes an astounding statement when he says ... He explains that the Bible details the current times so plainly that anyone should ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management ... radiology marketing programs at the annual Building Better Radiology Marketing Programs conference, ... Hotel in Fort Worth, Texas. Nine awards are given out in five categories. They ...
(Date:2/24/2017)... ... 2017 , ... Castle Farms, the celebrated Northern Michigan ... the winning couple announced on Feb. 14, 2017, on Facebook. The free wedding ... A Matter of Taste, Ryan Rousseau Enterprises, A Touch of Spring and Other ...
Breaking Medicine News(10 mins):